Cargando…
Fecal Microbial and Metabolic Profiles in Dogs With Acute Diarrhea Receiving Either Fecal Microbiota Transplantation or Oral Metronidazole
The aim was to characterize differences in fecal consistency, and fecal microbiota and metabolome profiles in dogs with acute diarrhea (AD) treated with either fecal microbiota transplantation as enema (FMT; n = 11) or oral metronidazole (MET; n = 7) for 7 days. On days 0, 7, and 28 fecal samples we...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7182012/ https://www.ncbi.nlm.nih.gov/pubmed/32363202 http://dx.doi.org/10.3389/fvets.2020.00192 |
_version_ | 1783526166283419648 |
---|---|
author | Chaitman, Jennifer Ziese, Anna-Lena Pilla, Rachel Minamoto, Yasushi Blake, Amanda B. Guard, Blake C. Isaiah, Anitha Lidbury, Jonathan A. Steiner, Jörg M. Unterer, Stefan Suchodolski, Jan S. |
author_facet | Chaitman, Jennifer Ziese, Anna-Lena Pilla, Rachel Minamoto, Yasushi Blake, Amanda B. Guard, Blake C. Isaiah, Anitha Lidbury, Jonathan A. Steiner, Jörg M. Unterer, Stefan Suchodolski, Jan S. |
author_sort | Chaitman, Jennifer |
collection | PubMed |
description | The aim was to characterize differences in fecal consistency, and fecal microbiota and metabolome profiles in dogs with acute diarrhea (AD) treated with either fecal microbiota transplantation as enema (FMT; n = 11) or oral metronidazole (MET; n = 7) for 7 days. On days 0, 7, and 28 fecal samples were obtained. Fecal samples from healthy dogs (HC; n = 14) were used for comparison. Samples were analyzed by the previously validated qPCR based canine Dysbiosis Index (DI; increased values indicate microbiota dysbiosis) and 16S rRNA gene sequencing. The fecal metabolome was analyzed using a previously validated targeted canine assay for fecal unconjugated bile acids, and untargeted metabolomics. Fecal consistency improved significantly in dogs treated with FMT and MET by day 7 and day 28 (p < 0.01) compared to day 0. However, on day 28 fecal consistency was significantly better in FMT compared to MET (p = 0.040). At day 0, dogs with AD had an altered microbiota indicated by significantly increased DI, decreased alpha-diversity, and altered beta-diversity. In the FMT group, the DI decreased over time, while MET led to a significant increase in the dysbiosis index at day 7 and 28 compared to FMT. Sequencing data revealed that in FMT microbial diversity and beta-diversity was similar to HC at day 28, while in MET these parameters were still significantly different from HC. In dogs treated with FMT, a decrease in cholic acid and the percentage of primary bile acids was observed, whereas treatment with metronidazole led to an increase in cholic acid at day 7 and an increase in percentage of primary bile acids over time. Based on untargeted metabolomics, dogs with AD had an altered fecal metabolome compared to HC. Dogs treated with FMT clustered closer to HC at day 28, while dogs treated with MET did not. In this pilot study, dogs with AD had significant differences in fecal microbiota and metabolome profiles. Dogs treated with MET still had altered microbial and metabolic profiles at day 28 compared to dogs treated with FMT or healthy dogs. |
format | Online Article Text |
id | pubmed-7182012 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71820122020-05-01 Fecal Microbial and Metabolic Profiles in Dogs With Acute Diarrhea Receiving Either Fecal Microbiota Transplantation or Oral Metronidazole Chaitman, Jennifer Ziese, Anna-Lena Pilla, Rachel Minamoto, Yasushi Blake, Amanda B. Guard, Blake C. Isaiah, Anitha Lidbury, Jonathan A. Steiner, Jörg M. Unterer, Stefan Suchodolski, Jan S. Front Vet Sci Veterinary Science The aim was to characterize differences in fecal consistency, and fecal microbiota and metabolome profiles in dogs with acute diarrhea (AD) treated with either fecal microbiota transplantation as enema (FMT; n = 11) or oral metronidazole (MET; n = 7) for 7 days. On days 0, 7, and 28 fecal samples were obtained. Fecal samples from healthy dogs (HC; n = 14) were used for comparison. Samples were analyzed by the previously validated qPCR based canine Dysbiosis Index (DI; increased values indicate microbiota dysbiosis) and 16S rRNA gene sequencing. The fecal metabolome was analyzed using a previously validated targeted canine assay for fecal unconjugated bile acids, and untargeted metabolomics. Fecal consistency improved significantly in dogs treated with FMT and MET by day 7 and day 28 (p < 0.01) compared to day 0. However, on day 28 fecal consistency was significantly better in FMT compared to MET (p = 0.040). At day 0, dogs with AD had an altered microbiota indicated by significantly increased DI, decreased alpha-diversity, and altered beta-diversity. In the FMT group, the DI decreased over time, while MET led to a significant increase in the dysbiosis index at day 7 and 28 compared to FMT. Sequencing data revealed that in FMT microbial diversity and beta-diversity was similar to HC at day 28, while in MET these parameters were still significantly different from HC. In dogs treated with FMT, a decrease in cholic acid and the percentage of primary bile acids was observed, whereas treatment with metronidazole led to an increase in cholic acid at day 7 and an increase in percentage of primary bile acids over time. Based on untargeted metabolomics, dogs with AD had an altered fecal metabolome compared to HC. Dogs treated with FMT clustered closer to HC at day 28, while dogs treated with MET did not. In this pilot study, dogs with AD had significant differences in fecal microbiota and metabolome profiles. Dogs treated with MET still had altered microbial and metabolic profiles at day 28 compared to dogs treated with FMT or healthy dogs. Frontiers Media S.A. 2020-04-16 /pmc/articles/PMC7182012/ /pubmed/32363202 http://dx.doi.org/10.3389/fvets.2020.00192 Text en Copyright © 2020 Chaitman, Ziese, Pilla, Minamoto, Blake, Guard, Isaiah, Lidbury, Steiner, Unterer and Suchodolski. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Veterinary Science Chaitman, Jennifer Ziese, Anna-Lena Pilla, Rachel Minamoto, Yasushi Blake, Amanda B. Guard, Blake C. Isaiah, Anitha Lidbury, Jonathan A. Steiner, Jörg M. Unterer, Stefan Suchodolski, Jan S. Fecal Microbial and Metabolic Profiles in Dogs With Acute Diarrhea Receiving Either Fecal Microbiota Transplantation or Oral Metronidazole |
title | Fecal Microbial and Metabolic Profiles in Dogs With Acute Diarrhea Receiving Either Fecal Microbiota Transplantation or Oral Metronidazole |
title_full | Fecal Microbial and Metabolic Profiles in Dogs With Acute Diarrhea Receiving Either Fecal Microbiota Transplantation or Oral Metronidazole |
title_fullStr | Fecal Microbial and Metabolic Profiles in Dogs With Acute Diarrhea Receiving Either Fecal Microbiota Transplantation or Oral Metronidazole |
title_full_unstemmed | Fecal Microbial and Metabolic Profiles in Dogs With Acute Diarrhea Receiving Either Fecal Microbiota Transplantation or Oral Metronidazole |
title_short | Fecal Microbial and Metabolic Profiles in Dogs With Acute Diarrhea Receiving Either Fecal Microbiota Transplantation or Oral Metronidazole |
title_sort | fecal microbial and metabolic profiles in dogs with acute diarrhea receiving either fecal microbiota transplantation or oral metronidazole |
topic | Veterinary Science |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7182012/ https://www.ncbi.nlm.nih.gov/pubmed/32363202 http://dx.doi.org/10.3389/fvets.2020.00192 |
work_keys_str_mv | AT chaitmanjennifer fecalmicrobialandmetabolicprofilesindogswithacutediarrheareceivingeitherfecalmicrobiotatransplantationororalmetronidazole AT zieseannalena fecalmicrobialandmetabolicprofilesindogswithacutediarrheareceivingeitherfecalmicrobiotatransplantationororalmetronidazole AT pillarachel fecalmicrobialandmetabolicprofilesindogswithacutediarrheareceivingeitherfecalmicrobiotatransplantationororalmetronidazole AT minamotoyasushi fecalmicrobialandmetabolicprofilesindogswithacutediarrheareceivingeitherfecalmicrobiotatransplantationororalmetronidazole AT blakeamandab fecalmicrobialandmetabolicprofilesindogswithacutediarrheareceivingeitherfecalmicrobiotatransplantationororalmetronidazole AT guardblakec fecalmicrobialandmetabolicprofilesindogswithacutediarrheareceivingeitherfecalmicrobiotatransplantationororalmetronidazole AT isaiahanitha fecalmicrobialandmetabolicprofilesindogswithacutediarrheareceivingeitherfecalmicrobiotatransplantationororalmetronidazole AT lidburyjonathana fecalmicrobialandmetabolicprofilesindogswithacutediarrheareceivingeitherfecalmicrobiotatransplantationororalmetronidazole AT steinerjorgm fecalmicrobialandmetabolicprofilesindogswithacutediarrheareceivingeitherfecalmicrobiotatransplantationororalmetronidazole AT untererstefan fecalmicrobialandmetabolicprofilesindogswithacutediarrheareceivingeitherfecalmicrobiotatransplantationororalmetronidazole AT suchodolskijans fecalmicrobialandmetabolicprofilesindogswithacutediarrheareceivingeitherfecalmicrobiotatransplantationororalmetronidazole |